key: cord-0713184-xnio8fce
authors: Rehman, Sabi Ur; Rehman, Shaheed Ur; Yoo, Hye Hyun
title: COVID-19 challenges and its therapeutics
date: 2021-08-05
journal: Biomed Pharmacother
DOI: 10.1016/j.biopha.2021.112015
sha: 7016252a26d02b9e49fee180c1d2a4a322b94cae
doc_id: 713184
cord_uid: xnio8fce

COVID-19, an infectious disease, has emerged as one of the leading causes of death worldwide, making it one of the severe public health issues in recent decades. nCoV, the novel SARS coronavirus that causes COVID-19, has brought together scientists in the quest for possible therapeutic and preventive measures. The development of new drugs to manage COVID-19 effectively is a challenging and time-consuming process, thus encouraging extensive investigation of drug repurposing and repositioning candidates. Several medications, including remdesivir, hydroxychloroquine, chloroquine, lopinavir, favipiravir, ribavirin, ritonavir, interferons, azithromycin, capivasertib and bevacizumab, are currently under clinical trials for COVID-19. In addition, several medicinal plants with considerable antiviral activities are potential therapeutic candidates for COVID-19. Statistical data show that the pandemic is yet to slow down, and authorities are placing their hopes on vaccines. Within a short period, four types of vaccines, namely, whole virus, viral vector, protein subunit, and nucleic acid (RNA/DNA), which can confer protection against COVID-19 in different ways, were already in a clinical trial. SARS-CoV-2 variants spread is associated with antibody escape from the virus Spike epitopes, which has grave concerns for viral re-infection and even compromises the effectiveness of the vaccines. Despite these efforts, COVID-19 treatment is still solely based on clinical management through supportive care. We aim to highlight the recent trends in COVID-19, relevant statistics, and clinical findings, as well as potential therapeutics, including in-line treatment methods, preventive measures, and vaccines to combat the prevalence of COVID-19.

highest number of cases, whereas the 65+ age group had the highest death rate. Further statistical details are presented in Table 1 .

Most patients with COVID-19 experience a minor to uncomplicated disease; however, approximately 14% develop a severe illness that requires hospitalization and oxygen treatment, with 5% requiring admission to an intensive care unit [22] . Acute respiratory distress syndrome (ARDS), septic shock, and sepsis are common complications in COVID-19 serious cases, as are various organ failures such as heart injury and acute kidney injury [23] . In addition, COVID-19 severe illness and mortality have been linked to older age and comorbidity such as heart failure, elevated blood pressure, lung disease, or diabetes [24] .

Epidemiologic investigation showed initial association of the seafood market of China Wuhan city is responsible for the beginning of the COVID-19 outbreak [25] . At the outbreak progression, the person-to-person spread is considered the primary mode of transmission. One USA-based study describes the first person-to-person transmission of COVID-19 in people in close contact with each other (about to range of 6 feet) [26] . Like the spread of influenza, when an individual coughs or sneezes, the respiratory droplets may contact the nearby people through the mouth or nose and may be inhaled into the lungs. Generally, symptomatic people are thought to be the most contagious. The life cycle of nCoV in human cells may provide enlightenment for viral transmission, and its potential therapeutic targets is shown in Figure 1 .

Fomite transmission is discussed in various studies that a person may also likely be infected with the COVID-19 by touching any object or surface that contains the virus, then touching his nose, mouth, or probably eyes. Still, it is not believed to be the primary way of virus transmission [27] .

The nCoV has been reported to be stable under experimental conditions on stainless steel and plastic surfaces correlated with copper and cardboard box surfaces. The virus is observed up to 72 hours after inoculation of textures with the virus. Nonporous substances such as glass and stainless steel were used to extract active viruses for 28days at 20°C. In contrast, the recovery of J o u r n a l P r e -p r o o f nCoV from porous surfaces was diminished.

A meta-analysis involving 936 neonates of COVID-19 mothers demonstrated vertical propagation but happened in a smaller number of cases. In addition, epidemiological evidence from many cases has shown that nCoV patients have live viruses in feces that indicate potential fecal-oral transmission [28] .

Several studies reported the nCoV transmission from asymptomatic infected individuals [29-34].

Next-level serology tests, which are under development, will facilitate understanding asymptomatic infections and epidemiological analysis [35, 36] .

Viruses constantly mutate upon replication. While most variations are insignificant, some render the virus more infectious or hostile, leading to serious health concerns. In October 2020, the SARS-CoV-2 lineage B.1.617 was discovered in India. It has now become prevalent in several regions within India and the United Kingdom and has spread to many other countries. The lineage is divided into three major subtypes (B1.617.1, B.1.617.2, and B.1.617.3), each with a unique set of spike mutations in the receptor-binding domain, and the N-terminal domain may enhance immune evasion. B.1.617.2, commonly known as variation Delta, is reported to spread more quickly than other variants [37] .

For COVID-19, the incubation period is estimated to be 14 days after exposure to the virus, typically 4 -5 days after exposure [18, 38, 39] .

Pneumonia is the most common and dangerous symptom of COVID-19 infection, which is characterized by fever, coughing, and shortness of breathing [39] [40] [41] [42] . Other symptoms include headache, fatigue, sore throat, increased sputum production, rhinorrhea, anorexia, hemoptysis, myalgias, and diarrhea [39, [43] [44] [45] [46] . On a chest CT scan, pneumonia, respiratory distress syndrome, acute heart injury, and white spots opacities can be seen, both of which can lead to death [47] [48] [49] . No specific clinical features for COVID-19 that clearly distinguish it from other respiratory viral infections.

Acute respiratory distress syndrome (ARDS) is a severe complication in patients with chronic disease. Arrhythmia, acute heart injury, and trauma were other complications [42, 51, 52] .

According to the world health organization, the recovery time seems about two weeks for mild infections and 3-6 weeks for severe cases.

-Prevention is better than cure‖, so, it is better to prevent COVID-19 by controlling its drastic spread rather than living with a hope of its precise treatment. However, like other respiratory infections (flu and the common cold), COVID-19 also required critical public health measures to decelerate the spread of the disease. Public health measures comprise everyday preventive actions, which includes [53] :  Strong immunity is the best approach to combat viruses. Therefore, adopting healthy habits, such as a balanced diet, adequate rest, oral hygiene, regular exercise, and avoiding excessive fatigue and stress, can boost immunity and effectively prevent viral infection [54, 55] .

For the optimal functioning of vital organs, existing therapeutic procedures for patient diagnosis and recovery focus primarily on symptomatic treatment and subsequent supportive care [56] .

Besides this, some medical centers prescribe antibiotics, antimalarials, and antivirals with limited J o u r n a l P r e -p r o o f clinical data. The primary interventions include bed rest, supportive care, adequate calories, water consumption, water balances and homeostasis, psychotherapy, oxygen therapy. Vit C and probiotics can also be used to improve the immune response [57, 58] . The very first step is to ensure that the infection is not further transmitted to family members, patients, and healthcare staff by proper insulation. Mild sickness should be treated in the home with appropriate advice on threat signs and strictly follow health practitioner recommendations. Its management incorporates treating cough and fever along with hydration and nutrition monitoring. In confirmed cases, avoid the use of routine antibiotics and antiviral drugs if otherwise recommended by an authorized physician. In hospitals, oxygen is recommended in hypoxic patients via a facial mask, nasal glands, high flux nasal cannula, or non-invasive ventilation.

Mechanical or artificial ventilation and extracorporeal membrane oxygen support may be needed if necessary, and renal replacement therapy should also be provided, depending on patient condition. Corticosteroid's role for COVID-19 is not established yet, so the centers for disease control and prevention (CDC) and WHO do not recommend these. Chinese guidelines suggest short-term corticosteroid use in COVID-19 derived ARDS at a low to moderate dose [59, 60] .

The World Health Organization has released comprehensive guidance on critical care management for COVID-19 [61] . Persons whose residence in the infected region are in danger of being exposed to this virus immediately notify the health care provider. Many pharmaceutical agents are being investigated for SARS CoV-2 antiviral activity. Any of them have been successfully presented for clinical trials based on in vitro evidence. Complete list of international clinical trials can be seen at www.clinicaltrials.gov and on WHO website. It is important to highlight that the efficacy of these investigational agents for COVID-19 is uncertain, due to lack of established data supporting the significance of any of these agents.

Remdesivir directly inhibits the RNA-dependent polymerase of nCoV, thus declared the most proficient drug molecule available for COVID-19. This drug has also proved efficient SARS-CoV, Ebola virus, and MERS-CoV [62] . Several randomized trials are in progress to test remdesivir efficacy for mild to extreme COVID-19 [63] . Remdesivir, a novel nucleotide analog formulated by Gilead Sciences Inc., is a wide-ranging antiviral treatment proven effective against nCoV in vitro lab tests [64] . It has been discussed by researchers for the Ebola virus in human J o u r n a l P r e -p r o o f beings. It has shown positive results in experimental animal studies to treat SARS and MERS [65] . The empathetic use of remdesivir as an investigational new drug was first reported in a case study of the COVID-19 patients in the United States [66] . Remdesivir's clinical impact against COVID-19 is uncertain at this time.

Chloroquine is an antiparasitic drug (antimalarial), prevents viruses from replicating in a pHdependent manner. Since the COVID-19 outbreak, various in vitro systems have been used to investigate the potential antiviral effects of chloroquine/hydroxychloroquine. In vitro studies have revealed the efficacy of chloroquine in suppressing SARS-CoV-2 infection when compared to that of other antiviral drugs, particularly favipiravir, penciclovir, nafamostat, nitazoxanide, and ribavirin [64] . These suggested the significant efficacy of chloroquine and hydroxychloroquine against nCoV. In contrast, hydroxychloroquine is more potent in antiviral action than chloroquine [64, 67, 68] . In China, Clinical trials evaluating the effectiveness of chloroquine or hydroxychloroquine for COVID-19 are in progress [69] . Studies on the monkey cells (Vero E6) suggested that chloroquine blocks glycosylation of the receptor inhibiting transmission of the virus into these cells and pathogenesis [69] . This application has yielded positive outcomes from nCoV infected human cell lines (Huh-7 cells) under a lab environment [70] . The time-of-addition experimental results revealed that chloroquine might interact with both the entry and post-entry stages of SARS-CoV-2 infection in Vero E6 cells. The authors speculated that chloroquine might be able to synergistically modify the immunological function to increase its antiviral efficacy.

The results of the time-of-addition assay suggested that hydroxychloroquine might restrict the entry and post-entry phases of SARS-CoV-2 in the cell and prevent viral genome release. In SARS-CoV-2-infected Vero E6 cells, chloroquine had a greater EC50 than that of hydroxychloroquine [71] . Hydroxychloroquine treatment mainly increased the size and number of endolysosomes, supporting its in vitro anti-SARS-CoV-2 effectiveness [72] .

Various animal models for SARS-CoV-2 infection have been developed by researchers using non-human primates to examine the therapeutic effects of hydroxychloroquine. Chen et al.

observed that there is no significant anti-SARS-CoV-2 impact of hydroxychloroquine either before therapy or early after infection (before the viral load peak) or late after infection (after the viral load peak) [73] . Clinical studies in hospitals have indicated that chloroquine and J o u r n a l P r e -p r o o f hydroxychloroquine prevent pneumonia exacerbation, encouraging negative viral conversion and shortening the illness course without apparent side effects [74] . Clinical trials in China have indicated that patients treated with chloroquine recover with normal pulmonary function, reduced fever, and decreased coughs faster than those treated with other antiviral medications [75] .

Perhaps most importantly, a clinical trial conducted in critically ill patients with showed that hydroxychloroquine might substantially lower the risk of mortality in these patients without causing any severe side effects [76] . increased T cell apoptosis, and an increased inflammatory response, while the regulatory effect of chloroquine/hydroxychloroquine on the immune response is not sufficiently effective to constrain the over-activation of the innate immune system [77] . A study suggested that the ORF3a gene of SARS-CoV-2 may prevent the fusion of autophagosomes and lysosomes, allowing SARS-CoV-2 to survive. This further complicates the function of autophagy and lysosomes in the SARS-CoV-2 life cycle [78] . It has been reported that the recommended chloroquine/hydroxychloroquine drug regimen for COVID-19 is considerably higher than that for malaria. Anxiety, insomnia, gastrointestinal complications, and cardiomyopathy have all been documented as side effects in clinical trials. Furthermore, the cardiotoxicity induced by chloroquine/hydroxychloroquine seems to be particularly relevant to the infection [73] .

Azithromycin has received considerable attention owing to its additional immunomodulatory effects on host defense reactions against chronic inflammations [79, 80] . It has the ability to modify immune responses and provide a long-term clinical benefit in various conditions like chronic obstructive pulmonary disease, non-eosinophilic asthma, cystic fibrosis, and non-fibrous cystic bronchiectasis [79] . Azithromycin increases the expression of IFN-β, PRR, and IFNλ genes and gene expression of PRR-stimulated genes [81] . It also raises the pH of the intracellular organelles of primary bronchial epithelial cells, such as trans-Golgi networks, which affects the overall virus activity of the cells. Increasing the pH of these organelles can adversely affect SARS-CoV and enzyme glycosylation [82] . Azithromycin inhibits the spike protein synthesis J o u r n a l P r e -p r o o f and slows down the viral entry in the cells, making it more difficult for the virus to spread [82] .

In vitro testing revealed that a combination of HCQ and azithromycin has a synergistic effect on nCoV at concentrations comparable to those found in human beings [83] . Aside from studies demonstrating the effectiveness of HCQ in combination with azithromycin, several studies have revealed severe side effects, limiting the use of this therapy in COVID-19 treatments [84] [85] [86] .

Combination treatment with existing medications is an effective strategy for improving the clinical therapeutic efficacy of drugs. Combination therapy of chloroquine with azithromycin has previously been prescribed in patients with SARS-CoV-2 infection [87] . According to a clinical study in France, the combination of hydroxychloroquine with azithromycin exhibits greater effectiveness than a single-drug regimen in terms of the viral clearance rate. In contrast, most studies have revealed that the combination of hydroxychloroquine with azithromycin does not result in positive clinical outcomes, similar to that in patients with SARS-CoV-2 infection [88] .

A retrospective multicenter cohort analysis of data from patients with SARS-CoV-2 infection at New York hospitals revealed no statistically significant difference in the in-hospital mortality rates among the various treatment groups [89] . A retrospective study of the ventilation risk in patients with COVID-19 in the United States revealed no significant differences associated with hydroxychloroquine and azithromycin treatment compared to the control group [90] . Clinical studies have consistently demonstrated that combining hydroxychloroquine with azithromycin has potential adverse effects in patients with COVID-19. In conclusion, most of the existing clinical trials of this combination therapy have not yielded encouraging results for future use in patients with COVID-19, primarily because of its treatment inefficiency and substantially adverse effects on the cardiovascular system [73] .

Capivasertib is a potent pan-AKT-kinase drug that inhibits AKT1, ACT2, and AKT3. This is an improvement strategy for anti-tumor medicines. Capivasertib is employed as an oral smallmolecule AKT inhibitor in clinical trials for drug-resistant breast cancer [91] . The luciferase assay was conducted to explore the role of capivasertib on SARS-CoV-2 S protein pseudo-type virus and VSV-dG in Vero cells. The analyses showed that capivasertib has a concentration- 

In vitro, the combination of these two HIV protease inhibitors exhibits better activity against SARS-CoV [93] , along with its in vivo proven efficacy against MERS-CoV [94] . The pharmacological use of this combination for COVID-19 treatment has been reported in case studies . China's current COVID-19 treatment guidelines involve 50 mg-200 mg intake for 10 days [98] . Ritonavir-boosted lopinavir (LPV) therapy does not seem to be the preferred treatment for salvage therapy in patients with extreme COVID-19. It may be beneficial to reduce nCoV loads early on to prevent radical secondary immune burst. Ritonavir boosted lopinavir efficacy (by enhancing pharmacokinetic/pharmacodynamics) in patients infected with nCoV. To minimize long-term virus transmission and its associated risk, the duration of the treatment must be provided for at least 14 days.

Umifenovir is also an antiviral medication that has been approved for influenza cure and prevention. However, it has been clinically tested and not authorized by the FDA until now. It is an inhibitor of membrane fusion and is recommended for an oral 10-day dose of 200 mg TDS [98] .

In hospitalized patients with pulmonary viral infections, like those caused by MERS-CoV and SARS-CoV, corticosteroids are commonly used to alleviate lung inflammation and reduce the chance of pulmonary injury. However, corticosteroids also suppress immune responses, which can obstruct viral clearance because it was noticed in certain MERS-CoV patients-considering J o u r n a l P r e -p r o o f that in these patients, the utilization of corticosteroids is already controversial, with ongoing clinical trials addressing the problem [99] .

Immunomodulatory agents can activate, inhibit, or modulate various immune system components, such as the immune system, innate and adaptive. Immunostimulants, such as those mentioned in Table 2 , are often recommended to improve the immune response to infectious diseases. Rate and extent of inflammation are directly linked to mortality and severity of COVID-19 patients, so interacting cytokine signaling via immunomodulatory techniques reduces overall hyper inflammation in such patients [100] .

As part of convalescent plasma therapy, plasma from recovered patients is utilized to treat patients with infections. Convalescent plasma therapy has been used to treat SARS [101, 102] , MERS [103] , Ebola [104] , Machupo virus [105] , and Junin virus [106] , although mixed therapeutic outcomes have been observed. Convalescent plasma is used as an adjunct to antiviral therapy. The protective effect of convalescent plasma might persist for several weeks to months.

After proper assessment of a donor, pheresis equipment can collect 200-600 mL of plasma.

Convalescent plasma therapy is a promising treatment option for COVID-19 [107] . A case series from China recently demonstrated better outcomes following COVID-19 convalescent plasma transfusion. The US Food and Drug Administration (FDA) recently approved the use of convalescent plasma as an emergency treatment for individuals with serious or life-threatening illnesses, such as COVID-19 [108] . Although convalescent plasma shows promising results in many cases, there remains insufficient evidence to support its use in the treatment of COVID-19.

According to several studies, convalescent plasma transfusion is safe and has a proven role in lowering the viral load and enhancing survival in critically ill patients. Convalescent plasma has therapeutic relevance, including alleviating clinical symptoms, although the decrease in mortality of critically ill patients is not statistically significant [109] . Only two adverse events were noted in a randomized trial [110] , including 52 patients receiving convalescent plasma therapy. In addition, a study found that transfusion of convalescent plasma was safe in hospitalized patients J o u r n a l P r e -p r o o f with COVID-19 [111] . These two reports confirmed the safety of convalescent plasma transfusion. The viral load and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) assays were used to assess the effectiveness of the treatment. After the transfusion, we found that the viral load had decreased and become negative after a few days (e.g., 3 days, 12 days, or 28 days) [112] . The mechanism of antibodies and peak time of viremia contribute to the first week following the infection being the optimal time to treat patients with plasma. According to a clinical study by Hegerova et al., [113] no patients died if they were treated with plasma within 7 days of admission, while the mortality rate in patients who received convalescent plasma transfusion after 7 days of hospitalization was 10%, compared to 30% in patients who did not receive plasma. This shows that the therapeutic effect of convalescent plasma transfusion is time-dependent, which is compatible with the viral illness mechanism. One study showed that a 37-year-old man with immunodeficiency and severe SARS-CoV-2 infection improved quickly after receiving convalescent plasma [114] .

Furthermore, there are no standardization or evidence-based reasons for donor selection, convalescent plasma quality control, or recipient transfusion indications due to a lack of understanding of the exact mechanism of convalescent plasma and precise therapeutics.

Herbal medicines are used extensively to cure and prevent numerous diseases and complications, including viral respiratory infections. Several traditionally used plant extracts have now been discovered to have promising antiviral properties. They can improve patients' health, but in COVID-19, there is still no confirmed proof of their efficacy. Allium sativum, Mentha piperita, Lianhua qing wen, and Zingiber officinale (ginger), Syzygium aromatic (Clove), Cassia fistula, Lagenaria breviflorus, Phyllanthus amarus, and Citrullus colocynthis are among the plants with proven efficacy against respiratory viral infections [115] . Glycyrrhiza glabra has traditionally is being used to combat cough and sore throat and to enhance digestion. Diammonium glycyrrhizinate has the anti-inflammatory properties of COVID-19 for regulating liver problems.

Lycoris radiata, Isatis indigotica demonstrated efficacy against SARS. Baicalein, a flavone derived from the roots of Scutellaria baicalensis and Scutellaria lateriflora, has been shown to block dengue virus penetration into the host cell and post-entry viral proliferation [116] .

Pelargonium sidoides and Taraxacum officinale (Dandelion) roots possess anti-influenza properties due to virus penetration and inhibited enzyme activity [117] . Herbal medicines that have the potential to stop viruses from replicating are often chosen as viable alternatives for combating viral outbreaks. As a result, G. glabra (licorice) and A. sativum (garlic) may be used as COVID-19 remedy alternatives. Clerodendrum inerme, a possible nCoV remedy plant, inhibits viral ribosome inactivation and protein translation [118] . Strobilanthes Cusia also prevents the development of RNA genomes, which makes it a good candidate for human coronaviruses [119] . [122] . An annual herbaceous plant called Andrographis paniculate has potent antiviral properties [123] . MPs with the ability to target HIV reverse transcriptase function, such as Ocimum sanctum (Basel), Solanum nigrum, and Vitex negundo, may be used to explore COVID-19 drug candidates [124] . Many HIV proteins and molecules are involved in SARS-CoV pathogenesis and are likely to be involved in nCoV pathogenesis [125] .

During pandemics, timeliness is a fundamental prerequisite for any drug development; thus, natural products could serve as suitable and effective options because their safety is instantly evaluated for combating patients. Therefore, we build a list of MPs summarized in Table 3 with their active molecule known for possessing antiviral activities. These could be suitable choices for combating the situations from the COVID-19 pandemic.

There are so many pharmacological interventions of interest, but with no or limited clinical data.

Such studies need to be evaluated in more extensive randomized trials to establish their efficacy and safety before presenting them to the world community.

Manufacturers and public labs worldwide were in a close race to discover vaccines for COVID- 

Since the nCoV outbreak, scientists worldwide have been exploring suitable therapeutics for COVID-19. They are working to identify short-term preventive alternatives and long-term vaccines to combat the COVID-19 threat. Despite significant improvements and favorable outcomes from vaccine candidate trials, numerous challenges remain, including the logistical challenges of mass production and delivery of millions or billions of doses to the global population, which would almost certainly be the most considerable constraint. In addition, due to the limitations of vaccines and the time-consuming process of developing new drugs, FDAapproved molecules with established efficacy for viruses and various inflammatory conditions are considered more attractive in COVID-19 therapy. Nevertheless, successful clinical trials are necessary to provide adequate evidence to ensure the safety and effectiveness of these drugs against COVID-19. SARS-CoV-2 variants spread are associated with antibody escape from the virus Spike epitopes, seriously concern re-infection and compromise the effectiveness of all types of the vaccines. Besides COVID-19 therapeutics, it is essential to establish an early diagnostic approach. Consistent research efforts and a thorough understanding of COVID-19 pathophysiology are expected to facilitate effective solutions. Despite the threats posed by the rapidly spreading viral outbreak, the world has seen impressive scientific coordination and collaboration that will undoubtedly act as a roadmap for future pandemic solutions.

The authors declare that they have no competing interests.

Recomm. Rep. 51 (RR-10) (2002) 1-29. Anti-GM-CSF [100] Convalescing plasma Short-term passive immunity is provided by neutralizing antibodies [134] Non-specific immunomodulators

Antibodies derived from combined plasma have short term passive immunity [135] Intravenous immunoglobulin

Deliver anti-inflammatory and antifibrotic results to inhibit cytokine reaction [136] Dexamethasone

Deliver anti-inflammatory and antifibrotic results to inhibit cytokine reaction [137] Interferon Antiviral and immunomodulator [138] Interferon-β-1b

Interferon-α-2b Antiviral and immunomodulator [139] Miscellaneous

Anti-inflammatory as well as immunomodulatory effects [140] Renin-Angiotensin-Aldosterone System Inhibitors Anti-inflammatory and immunomodulatory effects [142] Anti-inflammatory and immunomodulatory effects [144] Colchicine Anti-inflammatory and immunomodulatory effects [145] Note:

ACEi (angiotensin-converting enzyme inhibitors), IVIG (intravenous immunoglobulin), JAK (Janus kinase), GM-CSF (granulocyte macrophage colony stimulating factor), ARB (angiotensin II receptor blockers), TNF (tumour necrosis factor), IL (interleukin), IV (intravenous). Dengue virus [124] J o u r n a l P r e -p r o o f 

Return of the Coronavirus: 2019-nCoV

Structure, function, and evolution of coronavirus spike proteins

Coronavirus pathogenesis

Inferring the hosts of coronavirus using dual statistical models based on nucleotide composition

Alternative clinical specimens for the detection of SARS-CoV-2: A rapid review

From SARS to MERS, thrusting coronaviruses into the spotlight

Awareness, attitudes, and practices related to coronavirus pandemic among public in Saudi Arabia

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges

Origin and evolution of pathogenic coronaviruses

Bats and coronaviruses

Serological evidence of bat SARS-related coronavirus infection in humans

Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China

Evidence for camel-to-human transmission of MERS coronavirus

Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia

Predicting the receptor-binding domain usage of the coronavirus based on kmer frequency on spike protein

Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor

Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

The Severe Acute Respiratory Syndrome N

Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study

COVID-19: what is next for public health?

The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis

Coronavirus (COVID-19) Dashboard. Centers for Retrieved at

First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA

Guidelines for the prevention of intravascular catheter-related infections

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Clinical characteristics of 2019 novel coronavirus infection in China

Clinical features of patients infected with 2019 novel coronavirus in

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, China

Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage

Clinical characteristics of 140 patients infected by SARS-CoV-2 in

COVID-19): A Perspective from China

Symptoms of COVID-19

Chest CT findings in coronavirus disease-19 (COVID-19): Relationship to duration of infection

Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases

Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Estimating the risk of 2019 Novel Coronavirus death during the course of the outbreak in China

Clinical features and outcomes of 221 patients with COVID-19 in Wuhan

How to Protect Yourself & Others

Coronavirus infections and immune responses

Reducing mortality from 2019-nCoV: host-directed therapies should be an option

Weekly Epidemiological and Operational Updates

Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus

Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia

Treatment Guidelines. Retrieved at

Randomized trial of vitamin D supplementation to prevent seasonal influenza and upper respiratory infection in patients with inflammatory bowel disease

Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous

Study in High Risk Non-Hospitalized Patients with COVID-19. Retrieved at

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

First case of 2019 novel coronavirus in the United States

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

Chloroquine and hydroxychloroquine in covid-19

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Hydroxychloroquine/chloroquine as therapeutics for COVID-19: truth under the mystery

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

HIV protease inhibitors: a review of molecular selectivity and toxicity

Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

ORF3a of the COVID-19 virus SARS-CoV-2 blocks HOPS complex-mediated assembly of the SNARE complex required for autolysosome formation

Azithromycin: mechanisms of action and their relevance for clinical applications

Azithromycin suppresses Th1-and Th2-related chemokines IP-10/MDC in human monocytic cell line

Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells

Azithromycin and ciprofloxacin have a chloroquine-like effect on respiratory epithelial cells

In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect

An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine

Off-label‖ use of hydroxychloroquine, azithromycin, lopinavirritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

Adjunctive therapy with azithromycin for moderate and severe acute respiratory distress syndrome: a retrospective, propensity score-matching analysis of prospectively collected data at a single center

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19

Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19

Fulvestrant plus capivasertib for metastatic breast cancer

Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19

Treatment and vaccines for severe acute respiratory syndrome

Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset

Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR

Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment

Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore

Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China

Immune-mediated approaches against COVID-19

Pharmacoimmunomodulatory therapy in COVID-19

Stay safe: helpful herbal remedies in COVID-19 infection

Use of convalescent plasma therapy in SARS patients in Hong Kong, European Eur

Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital

Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection

The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States

Bolivian hemorrhagic fever: a report of four cases

Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19

Treatment of Argentine hemorrhagic fever with convalescent's plasma. 4433 cases

Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review

Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial

Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients

Early safety indicators of COVID-19 convalescent plasma in 5000 patients

Use of convalescent plasma in hospitalized patients with COVID-19: case series

Case report: convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19

Baicalin, a metabolite of baicalein with antiviral activity against dengue virus

COVID-19 and therapeutic drugs repurposing in hand: the need for collaborative efforts

Positive Therapeutic Role of Selected Foods and Plant on Ailments with a Trend Towards COVID-19: A Review

A systemic antiviral resistance-inducing protein isolated from Clerodendrum inerme Gaertn. is a polynucleotide: adenosine glycosidase (ribosomeinactivating protein

Antiviral action of tryptanthrin isolated from Strobilanthes cusia leaf against human coronavirus NL63

A review on antiviral activity of the Himalayan medicinal plants traditionally used to treat bronchitis and related symptoms

Gastrointestinal, selective airways and urinary bladder relaxant effects of Hyoscyamus niger are mediated through dual blockade of muscarinic receptors and Ca2+ channels

Mechanism & inhibition kinetics of bioassay-guided fractions of Indian medicinal plants and foods as ACE inhibitors

Plant derived antiviral products for potential treatment of COVID-19: A review

Plant Therapy of Corona Virus

Vaccines for COVID-19

Worldometers COVID-19 Coronavirus Pandemic. Retrieved at

Kineret®(anakinra) injection, solution prescribing information

Tocilizumab-A novel therapy for non-organ-specific autoimmune diseases

Highlights of prescribing information, These highlights do not include all the information needed to use LEVAQUIN® safely and effectively. See full prescribing information for LEVAQUIN®. LEVAQUIN®(levofloxacin) Tablet, Film Coated for Oral use

Baricitinib as potential treatment for 2019-nCoV acute respiratory J o u r n a l P r e -p r o o f disease

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed

Inhaled granulocyte/macrophage Colony-stimulating factor as treatment of pneumonia-associated acute respiratory distress syndrome

Treatment of 5 critically ill patients with COVID-19 with convalescent plasma

SARS: systematic review of treatment effects

Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial

Early, lowdose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single

A multicenter randomized prospective study on the treatment of infant bronchiolitis with interferon α1b nebulization

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Considerations for statin therapy in patients with COVID-19

Angiotensin II in inflammation, immunity and rheumatoid arthritis

Assessment of efficacy of Oseltamivir-Azithromycin combination therapy in prevention of Influenza-A (H1N1) pdm09 infection complications and rapidity of symptoms relief

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

Letter revoking EUA for chloroquine phosphate and hydroxychloroquine sulfate

Colchicine as an antiinflammatory and cardioprotective agent

Acacia nilotica: a plant of multipurpose medicinal uses

Anti-avian influenza virus H9N2 activity of aqueous extracts of Zingiber officinalis (Ginger) and Allium sativum (Garlic) in chick embryos

In vitro and in vivo effects of Peganum harmala L. seeds extract against influenza A virus

Discovery of inhibitory materials against PEDV corona virus from medicinal plants

Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus

Antiviral activity of carnosic acid against respiratory syncytial virus

Antiviral activity of crude extracts of Eugenia jambolana Lam. against highly pathogenic avian influenza (H5N1) virus

Antiviral activity of tannin from the pericarp of Punica granatum L. against genital Herpes virus in vitro

Antiviral effect and mode of action of methanolic extract of Verbascum thapsus L. on pseudorabies virus (strain RC/79)

Chemical compositions, antiviral and antioxidant activities of seven essential oils

Antimicrobial activity of stingless bee (Trigona sp.) propolis used in the folk medicine of Western Maharashtra

Evaluation of antioxidant and antiproliferative activities of dyeing plants

Evaluation of in vitro antiviral activity of Vitex Negundo L

In vitro antiviral effects of Peganum harmala seed extract and its total alkaloids against Influenza virus

Recovered Cases 173

Active cases in mild condition 12

Writing-Original draft preparation, Visualization Shaheed Ur Rehman: Conceptualization, Methodology, Writing-Original draft preparation

Hye Hyun Yoo: Supervision, Conceptualization, Writing-Reviewing and Editing

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: